Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Pelubiprofen SR and Eperisone SR in Healthy Males
NCT02071381Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pelubiprofen and eperisone in back pain (3 arms), sponsored by Daewon Pharm. Primary endpoints: Maximum Plasma Concentration (Cmax) of Pelubiprofen at Day 2, Area Under the Curve to the Last Measurable Concentration (AUClast) of Pelubiprofen at Day 2 and 4 more. Started Apr 2014; status: completed.
02
Drugs
pelubiprofeneperisone
03
Conditions
back pain
Beyond the preview
Go deeper on NCT02071381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071381.